title: Methylation status of TUSC3 is a prognostic factor in ovarian cancer.
abstract: BACKGROUND
  Current prognostic information in ovarian cancer is based on tumor stage, tumor grade, and postoperative tumor size. Reliable molecular prognostic markers are scarce. In this article, the authors describe epigenetic events in a frequently deleted region on chromosome 8p22 that influence the expression of tumor suppressor candidate 3 (TUSC3), a putative tumor suppressor gene in ovarian cancer.
  
  
  METHODS
  Messenger RNA expression and promoter hypermethylation of TUSC3 were studied in ovarian cancer cell lines and in tumor samples from 2 large, independent ovarian cancer cohorts using polymerase chain reaction-based methods.
  
  
  RESULTS
  The results indicated that TUSC3 expression is decreased significantly because of promoter methylation in malignant ovarian tumors compared with benign controls. Almost 33% of ovarian cancer samples had detectable TUSC3 promoter methylation. Furthermore, methylation status of the TUSC3 promoter had a significant and independent influence on progression-free and overall survival.
  
  
  CONCLUSIONS
  TUSC3 hypermethylation predicted progression-free and overall survival in ovarian cancer. The current observations suggested a role for N-glycosylating events in ovarian cancer pathogenesis in general and identified the epigenetic silencing of TUSC3 as a prognostic factor in this disease.
authors.affiliation: Department of Obstetrics and Gynecology, Division of Gynecology; Medical University of Vienna, Vienna, Austria.
authors.forename: Dietmar
authors.initials: D
authors.lastname: Pils
authors.forename: Peter
authors.initials: P
authors.lastname: Horak
authors.forename: Petr
authors.initials: P
authors.lastname: Vanhara
authors.forename: Mariam
authors.initials: M
authors.lastname: Anees
authors.forename: Michaela
authors.initials: M
authors.lastname: Petz
authors.forename: Angela
authors.initials: A
authors.lastname: Alfanz
authors.forename: Alfred
authors.initials: A
authors.lastname: Gugerell
authors.forename: Michael
authors.initials: M
authors.lastname: Wittinger
authors.forename: Andreas
authors.initials: A
authors.lastname: Gleiss
authors.forename: Veronika
authors.initials: V
authors.lastname: Auner
authors.forename: Dan
authors.initials: D
authors.lastname: Tong
authors.forename: Robert
authors.initials: R
authors.lastname: Zeillinger
authors.forename: Elena-Ioana
authors.initials: EI
authors.lastname: Braicu
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.forename: Michael
authors.initials: M
authors.lastname: Krainer
mesh_terms: D000328:Adult; D045744:Cell Line, Tumor; D019175:DNA Methylation; D018572:Disease-Free Survival; D005260:Female; D016147:Genes, Tumor Suppressor; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D011401:Promoter Regions, Genetic; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D008565:Membrane Proteins; C524338:TUSC3 protein, human; D025521:Tumor Suppressor Proteins